Literature DB >> 8425758

Evaluation of the new (1987) TNM classification for thoracic esophageal tumors.

H Kato1, Y Tachimori, H Watanabe, T Iizuka.   

Abstract

A total of 351 patients with thoracic esophageal carcinoma were prospectively classified according to the new (1987) TNM classification. Sixty-two patients received chemotherapy and/or radiotherapy without surgery. Esophagectomy was performed on 291 patients, among whom 139 underwent cervical, mediastinal and abdominal lymph adenectomy (3-field dissection). The number of stage IIB patients was unnaturally small, and the 3-year survival rates of stages IIA and IIB were similar. The survival curves for patients of T, N and M categories distributed well except for those of stages IIA and IIB. Numbers of patients in N and pN categories and those in M and pM categories showed poor coincidence. The 5-year survival rate for MI patients (10.5%) was too good, which suggested the mingling of patients with rather better prognosis. When MI (LYM) patients were excluded from MI, the 3-year survival rate fell to 0.3%. The 5-year survival rate for pMI (LYM) patients who underwent 3-field dissection was 38.2%. Survival rates and numbers of positive nodes showed negative correlation in patients who underwent 3-field dissection. According to these results, we propose the following revision in the next TNM classification: (1) to group stage IIA and stage IIB together to form Stage II; (2) to include cervical and coeliac lymph nodes among the regional lymph nodes, or to designate metastasis in non-regional lymph nodes separately from metastasis in viscera; and (3) to divide N1 into N1 and N2 according to the number of positive lymph nodes.

Entities:  

Mesh:

Year:  1993        PMID: 8425758     DOI: 10.1002/ijc.2910530208

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Successful treatment for esophageal carcinoma with lung metastasis by induction chemotherapy followed by salvage esophagectomy: report of a case.

Authors:  Shin Ichi Kosugi; Tatsuo Kanda; Tadashi Nishimaki; Satoru Nakagawa; Kazuhito Yajima; Manabu Ohashi; Katsuyoshi Hatakeyama
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

2.  Evaluating the rational extent of dissection in radical esophagectomy for invasive carcinoma of the thoracic esophagus.

Authors:  T Nishimaki; T Suzuki; Y Tanaka; S Nakagawa; K Aizawa; K Hatakeyama
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

3.  Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma.

Authors:  T Gotoda; Y Matsumura; H Kondo; H Ono; A Kanamoto; H Kato; H Watanabe; Y Tachimori; Y Nakanishi; T Kakizoe
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

4.  Clinical results of multimodality therapy for esophageal cancer with distant metastasis.

Authors:  Masakuni Sakaguchi; Toshiya Maebayashi; Takuya Aizawa; Naoya Ishibashi; Tsutomu Saito
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

5.  Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer.

Authors:  Koen Talsma; Pieter van Hagen; Brechtje A Grotenhuis; Ewout W Steyerberg; Hugo W Tilanus; Jan J B van Lanschot; Bas P L Wijnhoven
Journal:  Ann Surg Oncol       Date:  2012-03-07       Impact factor: 5.344

6.  Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma.

Authors:  T Ishikawa; M Furihata; Y Ohtsuki; H Murakami; A Inoue; S Ogoshi
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

7.  The prognostic significance of tumour cell proliferation in squamous cell carcinomas of the oesophagus.

Authors:  M Sarbia; F Bittinger; R Porschen; P Dutkowski; M Torzewski; R Willers; H E Gabbert
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

Review 8.  Diagnosis and treatment of esophageal neoplasms.

Authors:  H Kato
Journal:  Jpn J Cancer Res       Date:  1995-11

9.  Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy.

Authors:  M B Polee; W C J Hop; T C Kok; F A L M Eskens; M E L van der Burg; T A W Splinter; P D Siersema; H W Tilanus; G Stoter; A van der Gaast
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.